Sun Pharmaceutical Industries Limited has introduced STARIZO (Tedizolid Phosphate) to the Indian market, a novel antibacterial treatment targeting Acute Bacterial Skin and Skin Structure Infections (ABSSSI), particularly those caused by drug-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). This launch represents a significant advancement in addressing the growing concern of antibiotic-resistant infections in India. Skin […]
Sun Pharmaceutical Industries Limited has announced the completion of its strategic merger with Taro Pharmaceutical Industries Ltd. (NYSE: TARO), marking a significant consolidation in the pharmaceutical industry. With this merger, Taro has transitioned into a privately held company, wholly owned by Sun Pharma. Prior to this merger, Sun Pharma had been the majority shareholder of […]
Sun Pharmaceutical Industries Limited (Sun Pharma) has achieved a significant milestone in dermatology with the Australian Therapeutic Goods Administration (TGA)’s recent approval of Winlevi (clascoterone cream 1%). Indicated for the topical treatment of acne vulgaris in patients aged 12 and older, Winlevi introduces a novel mechanism of action to the Australian market, enriching Sun Pharma’s […]
In a notable development within the pharmaceutical industry, Sun Pharmaceutical Industries Limited has expressed a non-binding interest in acquiring shares of Taro Pharmaceutical Industries Ltd. Following Regulation 30 with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sun Pharmaceutical has updated its ongoing efforts to acquire Taro Pharmaceutical. Initial Proposal and […]
Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited have announced a licensing agreement for the co-marketing of Desidustat, an innovative oral anemia treatment for Chronic Kidney Disease (CKD) patients in India. This partnership signifies a significant advancement in CKD anemia treatment, offering a more convenient oral pill form as opposed to traditional injectable therapies. Licensing […]
Sun Pharmaceutical Industries Limited has made a significant announcement regarding its groundbreaking product, CEQUA (cyclosporine ophthalmic solution) 0.09%. The company has unveiled Phase 4 data showcasing CEQUA’s exceptional ability to induce sustained improvement in the signs and symptoms of dry eye disease (DED). CEQUA is an immunosuppressant and calcineurin inhibitor designed to enhance tear production […]
Sun Pharmaceutical Industries Ltd announced that the U.S. Food and Drug Administration (FDA) has officially accepted the New Drug Application (NDA) for their investigational drug, deuruxolitinib. This oral selective inhibitor of Janus kinases JAK1 and JAK2 seeks to offer relief to adults grappling with moderate to severe alopecia areata. With an 8mg twice-daily regimen, Sun […]
Sun Pharmaceutical Industries has unveiled positive results from two Phase 1 studies assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of GL0034, a novel long-acting GLP-1 receptor agonist, in non-obese and obese adults without diabetes. The findings will be presented in poster sessions at the American Diabetes Association’s 83rd Scientific Sessions in San Diego. One of […]
Sun Pharma Canada, a subsidiary of Sun Pharmaceutical Industries, has secured Health Canada’s approval for their pioneering acne treatment, WINLEVI (clascoterone cream 1%). This marks the first approval of an androgen receptor inhibitor for topical treatment of acne vulgaris in patients aged 12 and older, presenting a groundbreaking advancement in acne treatments for Canadian patients […]
MMP Industries, a Nagpur-based manufacturer of aluminum powders, aluminum foils, and aluminum conductors, has bagged its first commercial order from Sun Pharmaceutical Industries for the packaging of the pharma company’s products. According to MMP Industries, it had previously won an identical order from another major pharma company. MMP Industries said that through this order from […]
